Immune Thrombocytopenia

View All

pharma-news-for-x4-pharmaceuticals-ono-beigene-sanofi
X4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson & Johnson’s SIRTURO CHMP Approval; BeiGene’s Tislelizumab EC Approval; Sanofi’s Rilzabrutinib LUNA 3 Phase III Trial

FDA Greenlights XOLREMDI Capsules from X4 Pharmaceuticals for WHIM Syndrome Treatment X4 Pharmaceuticals has declared that the FDA has granted approval for XOLREMDI™ (mavorixafor) capsules to be utilized in individuals aged 12 and above who have WHIM syndrome (characterized by warts, hypogammaglobulinemia, infec...

Find More

Immune Thrombocytopenia Market
R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia

The Immune Thrombocytopenia market size in the 7MM was estimated to be approximately USD 2,527.72 million in 2017. The US accounts for the largest ITP Market size. A disorder that results in an isolated low platelet count, Immune thrombocytopenia (ITP), is an autoimmune disorder that results in convincing body...

Find More